ArticleBMJ open2020

Azathioprine immunosuppression and disease modification in Parkinson's disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol.

Julia C Greenland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.